Parkinson's disease age at onset genome‐wide association study: Defining heritability, genetic loci, and α‐synuclein mechanisms

Cornelis Blauwendraat(National Institutes of Health), Karl Heilbron(23andMe (United States)), Costanza L. Vallerga(The University of Queensland), Sara Bandrés‐Ciga(National Institutes of Health), Rainer von Coelln(University of Maryland, Baltimore), Lasse Pihlstrøm(Oslo University Hospital), Javier Simón‐Sánchez(German Center for Neurodegenerative Diseases), Claudia Schulte(German Center for Neurodegenerative Diseases), Manu Sharma(Zimmer Biomet (Netherlands)), Lynne Krohn(Montreal Neurological Institute and Hospital), Ari Siitonen(Oulu University Hospital), Hirotaka Iwaki(National Institutes of Health), Hampton L. Leonard(National Institutes of Health), Alastair J. Noyce(Queen Mary University of London), Manuela Tan(National Hospital for Neurology and Neurosurgery), J. Raphael Gibbs(National Institutes of Health), Dena Hernández(National Institutes of Health), Sonja W. Scholz(National Institutes of Health), Joseph Jankovic(Baylor College of Medicine), Lisa M. Shulman(University of Maryland, Baltimore), Suzanne Lesage(Inserm), Jean‐Christophe Corvol(Inserm), Alexis Brice(Inserm), Jacobus J. van Hilten(Leiden University Medical Center), Johan Marinus(Leiden University Medical Center), Johanna Eerola‐Rautio(University of Helsinki), Pentti J. Tienari(University of Helsinki), Kari Majamaa(Oulu University Hospital), Mathias Toft(Oslo University Hospital), Donald G. Grosset(Queen Elizabeth University Hospital), Thomas Gasser(German Center for Neurodegenerative Diseases), Peter Heutink(German Center for Neurodegenerative Diseases), Joshua Shulman(Baylor College of Medicine), Nicolas Wood(National Hospital for Neurology and Neurosurgery), John Hardy(MRC Prion Unit), Huw R. Morris(National Hospital for Neurology and Neurosurgery), David A. Hinds(23andMe (United States)), Jacob Gratten(Translational Research Institute), Peter M. Visscher(The University of Queensland), Ziv Gan‐Or(Montreal Neurological Institute and Hospital), Mike A. Nalls(National Institutes of Health), Andrew Singleton(National Institutes of Health)
Movement Disorders
April 7, 2019
Cited by 373Open Access
Full Text

Abstract

BACKGROUND: Increasing evidence supports an extensive and complex genetic contribution to PD. Previous genome-wide association studies (GWAS) have shed light on the genetic basis of risk for this disease. However, the genetic determinants of PD age at onset are largely unknown. OBJECTIVES: To identify the genetic determinants of PD age at onset. METHODS: Using genetic data of 28,568 PD cases, we performed a genome-wide association study based on PD age at onset. RESULTS: We estimated that the heritability of PD age at onset attributed to common genetic variation was ∼0.11, lower than the overall heritability of risk for PD (∼0.27), likely, in part, because of the subjective nature of this measure. We found two genome-wide significant association signals, one at SNCA and the other a protein-coding variant in TMEM175, both of which are known PD risk loci and a Bonferroni-corrected significant effect at other known PD risk loci, GBA, INPP5F/BAG3, FAM47E/SCARB2, and MCCC1. Notably, SNCA, TMEM175, SCARB2, BAG3, and GBA have all been shown to be implicated in α-synuclein aggregation pathways. Remarkably, other well-established PD risk loci, such as GCH1 and MAPT, did not show a significant effect on age at onset of PD. CONCLUSIONS: Overall, we have performed the largest age at onset of PD genome-wide association studies to date, and our results show that not all PD risk loci influence age at onset with significant differences between risk alleles for age at onset. This provides a compelling picture, both within the context of functional characterization of disease-linked genetic variability and in defining differences between risk alleles for age at onset, or frank risk for disease. © 2019 International Parkinson and Movement Disorder Society.


Related Papers

No related papers found

Powered by citation graph analysis